Significant clinical and paraclinical differences between the Brazilian (n=15) and European (n=27) SNN patients with anti-FGFR3 antibodies
| Parameters | Brazilian patients | European SNN patients | P value* |
| Clinical characteristics at onset | |||
| Age—median year (25th–75th percentile) | 44 (39–50) | 61 (50–68) | < 0.001 * |
| Sex—F/M (% of F) | 11/4 (73) | 16/11 (59) | 0.37 |
| Topography of reported symptoms—N (%) | |||
| Proximal UL | 10/15 (67) | 2/27 (7) | < 0.001 * |
| Distal LL | 3/15 (20) | 23/27 (85) | < 0.001 * |
| Purely LL | 0/15 (0) | 13/27 (48) | 0.001* |
| Asymmetry | 13/14 (93) | 6/25 (24) | < 0.001 * |
| Clinical characteristics at the first clinical exam | |||
| SNN score—median (25th–75th percentile) | 12.7 (10.5–12.7) | 11.0 (8.5–11.0) | 0.009* |
| Topography of reported symptoms—N (%) | |||
| Proximal UL | 12/15 (80) | 4/27 (15) | < 0.001 * |
| Asymmetry | 14/15 (93) | 8/27 (30) | < 0.001 * |
| Clinical signs at clinical exam—N (%) | |||
| Ataxia UL | 11/15 (73) | 8/27 (30) | < 0.001 * |
| Clinical characteristics at the last clinical exam | |||
| Topography of reported symptoms—N (%) | |||
| Distal LL | 4/15 (27) | 21/23 (91) | < 0.001 * |
| Proximal LL | 11/15 (73) | 4/23 (17) | < 0.001 * |
| Asymmetry | 14/15 (93) | 6/23 (26) | < 0.001 * |
| Clinical signs at clinical exam—N (%) | |||
| Global areflexia | 12/15 (80) | 6/23 (26) | 0.001* |
| Dysautonomia | 10/15 (67) | 2/23 (9) | < 0.001 * |
| Associated autoimmune diseases—N (%) | |||
| SS | 7/15 (47) | 1/26 (4) | 0.001* |
*The p values in bold and italic with the symbol ‘*’ are statistically significant after Bonferroni correction.
F, female;FGFR3, fibroblast growth factor receptor 3; LL, lower limbs; M, male; N, number; SNN, sensory neuronopathy; SS, Sjögren syndrome; UL, upper limbs.